一分钟看懂
这是一项关于急性淋巴细胞白血病的I 期研究，登记的药物或干预包括AUTO1，当前状态为招募中。登记地点显示中国New York、Philadelphia、San Antonio、Salt Lake City等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
AUTO1 · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The Mount Sinai Hospital · New York
- Children's Hospital of Philadelphia · Philadelphia
- Methodist Children's Hospital · San Antonio
- Primary Children's Hospital · Salt Lake City
- Hospital Vall d'Hebron · Barcelona
- Hospital Nino Jesus · Madrid
- Great Ormond Street Hospital for Children NHS Foundation Trust · London
- Royal Manchester Children's Hospital · Manchester
- Great North Children's Hospital · Newcastle upon Tyne
公开的入选条件
- * \< 18 years old at screening
- * ≥ 6 kg body weight at screening
- Pediatric patients with r/r B ALL
- r/r CD19-positive aggressive mature B including the B NHL subtypes: i) diffuse large B cell lymphoma, ii) Burkitt's lymphoma, iii) primary mediastinal large B cell lymphoma, iv) high-grade B cell lymphoma (not otherwise specified).
- * Karnofsky (age ≥ 10 years) or Lansky (age \< 10 year) performance status score ≥ 50%.
- * In participants with B ALL, local documentation of CD19 expression on leukemic blasts in the BM, peripheral blood, or cerebrospinal fluid or biopsy done no more than 30 days prior to consent.
- * Adequate renal, hepatic, pulmonary, and cardiac function.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06173518；登记信息更新于 2026-09-16。